Baolingbao Biology Co Ltd
Baolingbao Biology Co.,Ltd. researches and develops, manufactures, and sells a range of functional sugars in China. The company offers prebiotics, such as isomaltooligosaccharides, galactooligosaccharides, fructooligosaccharides, bagasse trisaccharides, and xylooligosaccharides; sugar alcohols and new sugar source products, including erythritol, trehalose, crystalline fructose, alodonose, and mal… Read more
Baolingbao Biology Co Ltd (002286) - Total Liabilities
Latest total liabilities as of September 2025: CN¥532.41 Million CNY
Based on the latest financial reports, Baolingbao Biology Co Ltd (002286) has total liabilities worth CN¥532.41 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Baolingbao Biology Co Ltd - Total Liabilities Trend (2006–2024)
This chart illustrates how Baolingbao Biology Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Baolingbao Biology Co Ltd Competitors by Total Liabilities
The table below lists competitors of Baolingbao Biology Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ZheJiang RIFA Digital Precision Machinery Co Ltd
SHE:002520
|
China | CN¥2.24 Billion |
|
Carter Bank and Trust
NASDAQ:CARE
|
USA | $4.43 Billion |
|
Hinova Pharmaceuticals Inc. A
SHG:688302
|
China | CN¥255.12 Million |
|
Hangzhou Huawang New Material Technology Co.Ltd.
SHG:605377
|
China | CN¥1.61 Billion |
|
Tanzanian Royalty Exploration Corp
NYSE MKT:TRX
|
USA | $76.66 Million |
|
Vitesco Technologies Group Aktiengesellschaft
PINK:VTSCY
|
USA | $4.50 Billion |
|
Kunshan Top A Intelligent Equipment
SHE:300836
|
China | CN¥788.71 Million |
|
Replimune Group Inc
NASDAQ:REPL
|
USA | $123.05 Million |
Liability Composition Analysis (2006–2024)
This chart breaks down Baolingbao Biology Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Baolingbao Biology Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Baolingbao Biology Co Ltd (2006–2024)
The table below shows the annual total liabilities of Baolingbao Biology Co Ltd from 2006 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥632.44 Million | -6.36% |
| 2023-12-31 | CN¥675.41 Million | -32.58% |
| 2022-12-31 | CN¥1.00 Billion | -17.60% |
| 2021-12-31 | CN¥1.22 Billion | +19.62% |
| 2020-12-31 | CN¥1.02 Billion | +6.79% |
| 2019-12-31 | CN¥951.76 Million | -8.24% |
| 2018-12-31 | CN¥1.04 Billion | +78.29% |
| 2017-12-31 | CN¥581.79 Million | +37.40% |
| 2016-12-31 | CN¥423.43 Million | -2.76% |
| 2015-12-31 | CN¥435.44 Million | +37.49% |
| 2014-12-31 | CN¥316.69 Million | +31.48% |
| 2013-12-31 | CN¥240.88 Million | -18.43% |
| 2012-12-31 | CN¥295.31 Million | -16.12% |
| 2011-12-31 | CN¥352.06 Million | +6.86% |
| 2010-12-31 | CN¥329.46 Million | -21.84% |
| 2009-12-31 | CN¥421.50 Million | -16.68% |
| 2008-12-31 | CN¥505.85 Million | +23.80% |
| 2007-12-31 | CN¥408.62 Million | +3.34% |
| 2006-12-31 | CN¥395.40 Million | -- |